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Abstract:  The  potent  mitogenic  toxin  from  Pasteurella  multocida  (PMT) is  the major 
virulence factor associated with a number of epizootic and zoonotic diseases caused by 
infection with this respiratory pathogen. PMT is a glutamine-specific protein deamidase 
that acts on its intracellular G-protein targets to increase intracellular calcium, cytoskeletal, 
and mitogenic signaling. PMT enters cells through receptor-mediated endocytosis and then 
translocates into the cytosol through a pH-dependent process that is inhibited by NH4Cl or 
bafilomycin A1. However, the detailed mechanisms that govern cellular entry, trafficking, 
and translocation of PMT remain unclear. Co-localization studies described herein revealed 
that while PMT shares an initial entry pathway with transferrin (Tfn) and cholera toxin 
(CT),  the  trafficking  pathways  of  Tfn,  CT,  and  PMT  subsequently  diverge,  as  Tfn  is 
trafficked  to  recycling  endosomes,  CT  is  trafficked  retrograde  to  the  ER,  and  PMT  is 
trafficked to late endosomes. Our studies implicate the small regulatory GTPase Arf6 in the 
endocytic trafficking of PMT. Translocation of PMT from the endocytic vesicle occurs 
through  a  pH-dependent  process  that  is  also  dependent  on  both  microtubule  and  actin 
dynamics, as evidenced by inhibition of PMT activity in our SRE-based reporter assay, 
with nocodazole and cytochalasin D, respectively, suggesting that membrane translocation 
and cytotoxicity of PMT is  dependent  on its  transfer to  late endosomal compartments.  
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In contrast, disruption of Golgi-ER trafficking with brefeldin A increased PMT activity, 
suggesting that inhibiting PMT trafficking to non-productive compartments that do not lead 
to  translocation,  while  promoting  formation  of  an  acidic  tubulovesicle  system  more 
conducive to translocation, enhances PMT translocation and activity.  
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1. Introduction  
Toxinogenic  strains  of  Pasteurella  multocida  are  associated  with  a  number  of  epizootic  and 
zoonotic diseases, including atrophic rhinitis in swine, and respiratory disease and pasteurellosis in 
rabbits, cattle, and other domestic and wild animals (reviewed in [1,2]). In humans, P. multocida is 
associated with dermonecrosis and bacteremia from animal bite wounds or respiratory infections from 
chronic zoonotic exposure to infected livestock or pets (e.g., rabbits, cats, dogs) [3]. The 1285-amino 
acid,  multi-functional  protein  toxin  produced  by  P.  multocida  serotype  A  and  D  strains  (PMT) 
experimentally induces all of the major symptoms of these diseases [4], and has been proposed as a 
contributor  to  post-exposure  bone  loss  [1,5],  weight  reduction  and  fat  loss  [6–8],  immune  
modulation [9], and potential cancer development [8,10]. 
Intoxication  of  mammalian  cells  by  PMT  activates  a number of different  intracellular  calcium, 
cytoskeletal, and mitogenic (MAPK and JAK/STAT) signaling pathways (reviewed in [11]) through 
the activity of its C-terminal C3 domain [12,13], which acts as a glutamine-specific deamidase of its 
targeted heterotrimeric G-protein  subunits [14]. Since PMT activates several mitogenic signaling 
pathways that lead to downstream activation of serum response element (SRE) transcription [15,16], it is 
possible to use an SRE-based luciferase reporter system to measure intracellular activity of PMT [13]. 
Although the intracellular action of PMT is becoming more defined [17], little is known about the 
trafficking pathways the toxin exploits to gain access to its cytosolic targets. The lag time between 
toxin  treatment  and  toxin  activity  supports  the  assertion  that  PMT  is  an  intracellularly-acting  
toxin [18]. In addition, it has been demonstrated that the addition of PMT-specific antibodies or the 
addition of weak bases, such as methylamine, only inhibit PMT activity if added during the early stages 
of intoxication [18]. Furthermore, exposure of cells to PMT at 4 ° C results in no detectable PMT 
activity [18], suggesting that endocytic trafficking involving a pH-dependent step is necessary for PMT 
intoxication. This was confirmed by use of bafilomycin A1 (BFA), an inhibitor of the vacuolar ATPase 
proton pump [19], as measured by its inhibition of PMT-mediated phosphorylation of focal adhesion 
kinase  (FAK)  [20].  Furthermore,  when  PMT  was  bound  to  the  cell  surface  and  endocytosis  was 
inhibited, there was an increase in PMT activity upon exposing the cells to an acidic pH, suggesting 
that the drop in pH caused PMT to translocate directly across the plasma membrane [20]. In this same 
study, PMT was found to insert into lipids in a pH-dependent manner and at a pH similar to that at 
which the protein is reported to unfold [21]. Together, these data support a model in which PMT is 
endocytosed and trafficked through a low pH compartment where PMT unfolds, then inserts into and 
translocates across the vesicle membrane to presumably deliver the catalytic domain into the cytosol.  Toxins 2011, 3                       
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The  small  GTPase  Arf6  is  involved  in  trafficking  of  ligands  from  the  plasma  membrane  and 
localizes  both  to  the  plasma  membrane  and  to  internal  punctate  structures.  Intra-endosomal 
acidification  has  been  shown  to  result  in  recruitment  of  Arf6,  along  with  its  cognate  GDP/GTP 
exchange  factor  (GEF)  and  an  ADP-ribosylation  factor  nucleotide  site  opener  (ARNO),  to  the 
endosomal  membrane  [22]. Once at  the  endosomal  membrane, Arf6 binds to the c-subunit of the 
vacuolar ATPase, while ARNO binds to the a2-isoform [23]. Internal structures that label for Arf6 are 
tubulovesicular in shape, and Arf6 can be visualized on tubule extensions, suggesting that Arf6 also 
plays a role in recycling back to the plasma membrane [24]. It has been demonstrated that Arf6 positive 
vesicles can recruit markers of the early endosome, such as early endosome antigen 1 (EEA1), to their 
surface  [25].  Alternatively,  the  fusion  of  primary endocytic vesicles  with  early endosomes  is  also 
regulated by Rab5, another small regulatory GTPase involved in intracellular trafficking of recycling 
endosomes [26], and EEA1 [27]. This fusion is mediated by the activity of PI-3 kinase, as specific 
inhibitors of PI-3 kinase such as LY294002 prevent this fusion from occurring [28].  
Transferrin  (Tfn)  and  its  cognate  receptor  are  ubiquitous  iron-uptake  proteins  that  are  
well-characterized markers for Rab5-containing clathrin-coated vesicles and recycling endosomes [29]. 
The trafficking of Tfn through Arf6 compartments seems to differ according to cell type. In HeLa cells 
Tfn localizes to a separate compartment from Arf6 [30], while in CHO cells and HEK-293T cells 
transferrin localizes to the same compartment as Arf6 [31,32]. While overexpression of wildtype Arf6 
does not affect the function of Arf6 or its distribution and localization in cells, specific mutations that 
interfere with GDP/GTP binding and/or hydrolysis do [24]. The constitutively active, GTP-hydrolysis-
defective mutants of Arf6 (Q67L) localizes to the plasma membrane and causes a reduction in the 
formation of endosomes, whereas the dominant negative, GTP-binding-defective Arf6 mutant (T27N) 
localizes almost exclusively in endosomes [24]. Overexpression of Arf6 Q67L mutant results in an 
increase in cell surface binding of Tfn, but also in a decrease in the rate of internalization of Tfn [33], 
suggesting  that  while  the  mutant  results  in  an  increase  in  binding  of  the  ligand  it  is  unable  to 
subsequently internalize it. Alternatively, overexpression of the Arf6 T27N mutant results in a decrease 
in the amount of cell surface-bound Tfn and prevents reappearance of cell surface Tfn receptors [33].  
Cholera toxin (CT), a multi-subunit protein toxin secreted by Vibrio cholerae, has been shown to 
recruit Arf6 to endosomal membranes during its cellular intoxication process [34]. Arf6 also serves as 
an allosteric activator of the CT-catalyzed ADP-ribosylation of Gs [35,36], with crystal structures of 
an Arf6-CT complex lending insight into how this occurs  through changes in the active site loop 
structure that facilitates NAD binding  [37]. Furthermore,  CT has  been shown to increase rates of  
intra-endosomal  acidification  [34]  and  while  intra-endosomal  acidification  is  not  thought  to  be 
important for translocation of CT, the trafficking of CT through a low pH compartment has been 
demonstrated to be important for proteolytic activation of the catalytic subunit [38]. These observations 
suggest the possibility that PMT may use the same initial trafficking pathway as Tfn and/or CT, and 
may be trafficked to an acidified Arf6-positive endosome, from where it may translocate.  
Although we hypothesize that PMT shares a common initial entry pathway with CT, CT has a 
KDEL  signal  and  undergoes  further  retrograde  trafficking  through  the  Golgi  to  the  endoplasmic 
reticulum (ER), where the catalytic subunit of CT escapes to the cytosol [39]. It has been demonstrated 
that treatment with brefeldin A (BFA), a fungal metabolite that interrupts trafficking between the Golgi Toxins 2011, 3                       
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apparatus and the ER [40], disrupts CT activity implicating the importance of Golgi-ER trafficking for 
CT [41]. Since we propose that PMT translocates from the acidified endosome, treatment with BFA 
should have no effect on PMT activity and would provide a useful tool for discerning where the entry 
pathways of PMT and CT diverge. On the other hand, although PMT translocation is pH dependent, it 
is not clear whether translocation occurs from early endosomes or late endosomes. Since it has been 
shown that vectoral transport from early to late endosomes is dependent on microtubule and actin 
dynamics [27,42], disruption of the microtubule network with nocodazole or actin polymerization with 
cytochalasin D should inhibit PMT translocation and cytotoxicity. 
Our studies reported herein aim to elucidate the trafficking events involved in PMT intoxication. In 
particular,  we  describe  the  role  of  the  small  GTPase  Arf6  in  the  uptake  and trafficking  of PMT. 
Furthermore, we show that PMT shares the same initial pathway for entry into the cell as Tfn and CT, 
but then the PMT trafficking pathway diverges from the others to a late-endosomal compartment, from 
which PMT then translocates in a pH-dependent manner. 
2. Materials and Methods  
2.1. Plasmid Constructs 
The pcDNA3.1 vector encoding the wild-type Arf6 protein was obtained from the Missouri S&T 
cDNA  Resource  Center.  pcDNA3.1-Arf6  T27N,  pcDNA3.1-Arf6  T44N,  pcDNA3.1-Arf6  Q67L, 
pcDNA3.1-Arf6 T157A, pcDNA3.1-Arf6 G2A/Q67L, and pcDNA3.1-Arf6 G2A/T157A mutants were 
created by a two step PCR with the first step introducing the mutation and a second step amplifying the 
entire cDNA using the primers listed in Table 1. The cDNA was then digested with XhoI and EcoRI 
and inserted into the pcDNA3.1 vector. Constructs were verified by sequencing. 
Table 1. Primers used in construction of Arf6 mutants. 
Primer Name  Sequence (5' to 3') 
Arf6 T27N  CGCGGCCGGCAAGAACACAATCCTGTACAAGTTG 
Arf6 T27Nr  CAACTTGTACAGGATTGTGTTCTTGCCGGCCGCG 
Arf6-T44N  GACCACCATTCCCAATGTGGGTTTCAACGT 
Arf6-T44Nr  ACGTTGAAACCCACATTGGGAATGGTGGTC 
Arf6 Q67L  ATGTGGGCGGCCTGGACAAGATCCG 
Arf6 Q67Lr  CGGATCTTGTCCAGGCCGCCCACAT 
Arf6 Q67L 2  TATGGGATGTGGGCGGCCTGGACAAGATCCGGCCGCTCTG 
Arf6 Q67Lr 2  CAGAGCGGCCGGATCTTGTCCAGGCCGCCCACATCCCATA 
Arf6 T157A  TCCTGTGCCGCCTCAGGGGACG 
Arf6 T157Ar  CGTCCCCTGAGGCGGCACAGGA 
Arf6 G2A  GTGGAATTCACCATGGCGAAGGTGCTATCCAAAATCTTC 
Arf6 G2Ar  GAAGATTTTGGATAGCACCTTCGCCATGGTGAATTCCA 
pcDNAF  CGCAAATGGGCGGTAGGCGTG 
BGHr2  CAACAGATGGCTGGCAAC 
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2.2. Expression, Purification and Quantification of PMT and PMTb-GFP 
Recombinant PMT (rPMT) was expressed and purified as previously described [13]. rPMT was 
expressed in Escherichia coli TOP10 cells (Invitrogen) in the pTHC-ToxA vector under the induction 
of  IPTG.  The  cell  extract  was  purified  by  Ni
2+-NTA-agarose  chromatography  (Qiagen).  Fractions 
containing  rPMT  were  further  purified  by  FPLC  using  HiTrapQ  anion  exchange  chromatography 
(Amersham)  and  desalted  with  a  PD-10  column  (Amersham).  Removal  of  the  His6-tag  was 
accomplished according to manufacturer’s protocol using a Thrombin Cleavage Capture Kit (Novagen) 
and rPMT was further purified by FPLC using a HiTrapQ anion exchange column and a Superdex  
200  sizing  column.  Fractions  containing  rPMT  were  concentrated  using  Centricon  filter  units 
(Millipore) and desalted using a PD-10 column with phosphate-buffered saline (PBS) containing 10% 
glycerol. The concentration of rPMT was determined by NIH Image J digital image analysis of Pierce 
GelCode  Blue-stained  SDS-PAGE  gels  using BSA as  the standard. Toxin  samples  were stored at  
−80 ° C until use. 
An  N-terminal  fragment  of  PMT  (residues  1–568)  with  GFP  at  the  C-terminus  (denoted  as  
PMTb-GFP) was expressed in BL21 cells (Novagen) in the pET21b vector (Novagen). The cell extract 
was purified by Ni
2+-NTA-agarose chromatography (Qiagen). Fractions containing rPMT were further 
purified by FPLC using HiTrapQ anion exchange chromatography (Amersham) and desalted with a 
PD-10 column (Amersham). Concentration was determined as described above. 
2.3. Cell Culture 
HEK 293-T cells (ATCC # CRL-11268) and Swiss 3T3 cells (ATCC # CCL-92) were cultured and 
maintained at 37 ° C and 5% CO2 in DMEM (Gibco) with 10% fetal bovine serum (FBS), 100 U/mL 
penicillin G, and 100 µg/mL streptomycin. 
2.4. SRE Assay 
HEK 293-T cells at 80% confluency were replated at a 1:7 ratio in 24 well plates. The next day the 
medium was changed to DMEM with 2% FBS, penicillin and streptomycin, and cells were transfected 
using the CaCl2 method [43]. The plasmid DNA (0.25 µg/mL of pSRE-luc (Stratagene), 0.025 µg/mL 
p-Renilla-TK (pGL 7.4 hRluc/TK, Promega), 0.025 µg/mL pcDNA3-Gq and 0.1 µg/mL of a vector 
encoding the protein of interest) in a solution of 250 mM CaCl2 was added dropwise to a solution of  
2×   HEPES-buffered  saline  while  vortexing.  The  solution  was  incubated  at  room  temperature  for  
20 min and then added dropwise to each well. Cells were incubated for 7 h, after which the medium 
was changed without or with rPMT (at a final concentration of 100 ng/mL). After 16 h of rPMT 
treatment the medium was removed, and cells were lysed by adding 150 µL of 1×  Passive Lysis Buffer 
(Promega) and incubating for 15 min on a rotary shaker. Cell lysates were analyzed using the Dual 
Luciferase  Assay  System  (Promega),  according  to  manufacturer’s  protocol.  Luminescence  was 
measured using a Synergy-HT multi-detection microplate reader (BioTek) and results were reported as 
relative light units (sensitivity = 100, integration time = 1 s). Toxins 2011, 3                       
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2.5. Data Analysis 
SRE activity was determined by dividing the firefly luciferase activity by the Renilla luciferase 
activity. Within each experiment SRE activity was averaged and the average of the rPMT treated was 
divided by the average of the untreated SRE activity to determine the fold activation. In the Arf6 
overexpression experiments the fold activation for the test vector was then divided by fold activation of 
the empty vector to obtain the fold activation, normalized to control. In the Arf6 experiments, data is 
expressed as the mean ±  S.D. of results from eight independent experiments repeated in triplicate. In 
the  chemical  inhibitor  experiments,  data  is  expressed  as  the  mean  ±  S.D.  of  results  from  three 
independent experiments repeated in triplicate. A student’s t-test was then used to compare the fold 
activation  values  of  each  test  vector  to  the  empty  vector  control  in  the  Arf6  experiments  and  to 
compare  the  fold  activation  values  of  the  treated  and  untreated  in  the  experiments  using  
chemical inhibitors. 
2.6. Treatment of Cells with Toxins and Inhibitors 
HEK 293-T cells at 80% confluency, maintained as described above, were plated at a 1:7 ratio in 
24-well  plates.  The  next  day  the  medium  was  changed  to  DMEM  with  2%  FBS,  penicillin  and 
streptomycin, and cells were transfected using the CaCl2 method, as described above. Each well was 
transfected with 250 ng/mL of pSRE-luc (Stratagene), 25 ng/mL p-Renilla-TK (pGL 7.4 hRluc/TK, 
Promega), and 25 ng/mL pcDNA3-Gq. Cells were incubated for 7 h at 37 ° C after which medium 
containing the indicated inhibitor was added to the wells. Stock solutions of 700 nM bafilomycin A1 
(BAF) (Alexis Biochemicals), 200 µM cytochalasin D (Sigma), 100 µM nocodazole (Sigma), and 
700 µM LY294002 (Alexis Biochemicals) were created by dissolving the inhibitor in DMSO. A stock 
solution of 140 mM NH4Cl (J. T. Baker) was created by dissolving NH4Cl in water. The stock solution 
of  70  µM  brefeldin  A  (BFA)  (Alexis  Biochemicals)  was  created  by  dissolving  the  inhibitor  in 
methanol.  After  15  min  incubation  with  the  inhibitor,  rPMT  was  added  to  the  wells  at  a  final 
concentration of 100 ng/mL. After 16 h of rPMT treatment the media was removed and the cells were 
lysed by adding 150 µL of 1×  Passive Lysis Buffer (Promega) and incubating for 15 min on a rotary 
shaker. Cell lysates were analyzed using the Dual Luciferase Assay System (Promega), according to 
the  manufacturer’s  protocol.  Luminescence  was  measured  using  a  Synergy-HT  
multi-detection microplate reader (BioTek). SRE activity was determined as described above, and the 
data  was  expressed  as  the  mean  ±  S.D.  of  results  from  three  independent  experiments  repeated 
in triplicate. 
2.7. Western Blot Analysis 
HEK 293-T cell lysates were subjected to western blot analysis. Lysates were separated on a 10% 
SDS-PAGE acrylamide gel and subsequently transferred to a nitrocellulose membrane. Membranes 
were blocked for 30 min at room temperature in 5% powdered milk in 10 mM Tris-blocking buffer  
(10 mM Tris-HCl, pH 8.0, 2 mM EDTA, 50 mM NaCl, 0.1% NaI). Membranes were then incubated 
overnight at 4 °C  with the indicated primary antibody in 5% milk in 10 mM Tris-blocking buffer. 
Membranes  were  then  washed  5  times  for  3  min  in  1%  Tween  in  100  mM  Tris-washing  buffer  Toxins 2011, 3                       
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(100 mM Tris-HCl, pH 8.0, 200 mM NaCl) before incubation at room temperature with the appropriate 
secondary antibody. The following primary antibodies were used: mouse anti-phospho-Akt (Ser473) 
587F11 (4051, Cell Signaling) and mouse anti-Akt (9272, Cell Signaling). HRP-conjugated secondary 
antibodies used included: goat anti-mouse IgG (115-036-003, Jackson ImmunoResearch Laboratories, 
Inc.) and goat anti-rabbit (sc-2004, Santa Cruz Biotechnology). After washing 5 times for 3 min each 
with Tris-washing buffer, the membranes were then developed using Pierce
® ECL Western Blotting 
Substrate (Thermo Scientific) and HyBlot CL autoradiography film (Denville Scientific Inc.). Images 
were then scanned and prepared using Adobe Photoshop. Blots shown are representative of at least 
three independent experiments. 
2.8. Colocalization Studies 
Swiss 3T3 cells at 80% confluency were plated in a 1:12 ratio on 18mm circular coverslips (Fisher) 
in 12 well plates containing DMEM with 1% BGS. The next day the medium was changed 3–4 h 
before toxin treatment. If chemical inhibitors were used, medium containing the indicated inhibitor, 
final concentration of 30 mM NH4Cl or 1 µM BFA, was added to the wells 15 min before toxin 
treatment. After 15 min incubation with the inhibitor, PMTb-GFP was added to the wells at a final 
concentration  of  100  µg/mL.  CT  subunit  B  Alexa  Fluor
®-594  conjugate  (CTxB-594)  (Molecular 
Probes) was added to the wells at a final concentration of 1 µg/mL. After 1 or 3 h of toxin treatment 
the medium was removed and the coverslips were fixed with 3.7% formaldehyde in DMEM 10% BGS 
for  20  min.  Coverslips  were  washed  3  times  with  1×   PBS  and  mounted  onto  a  
No. 1 ½, 22 ×  50 mm coverslip (Corning) using ProLong Gold mounting media (Invitrogen). Confocal 
microscopy  was  carried  out  with  a  Zeiss  LSM  710  NLO  (Zeiss).  Images  were  generated  as  
described above. 
2.9. Labeling of the Endosomes with Transferrin-Texas Red 
Swiss 3T3 cells were plated at low density (10
3 cells per well) on coverslips in a 12-well plate and 
grown overnight in 10% BGS-DMEM. Before toxin treatment, the cells were washed 2 times with  
1×  PBS containing gentamicin and PMTb-GFP was added to the wells at a final concentration of  
100–260 μg/mL of PMTb-GFP. After 15-h incubation, 20 μg/mL of Transferrin-Texas Red (Tfn-TR) 
was added to each well and incubated for an additional 3.5 h. Toxin treatment was terminated by 
washing the wells with 1×  PBS and fixing the cells with 3.7% formaldehyde in PBS. Coverslips were 
washed 3 times with 1×  PBS and mounted using mounting medium consisting of 1×  PBS, 180 mg/mL 
polyvinyl  alcohol  (PVA),  27%  glycerol  and  2  g/L  DABCO  anti-fade  reagent  (1,4-diazabicyclo-
[2.2.2]octane). Confocal microscopy was performed using a Carl Zeiss Laser Scanning Microscope 
(LSM 510) with a 40×  oil-immersion objective. Images were generated as described above. 
3. Results and Discussion 
3.1. Colocalization of PMTb with Tfn 
A number of bacterial toxins are internalized via receptor-mediated endocytosis, yet the precise 
pathway taken varies among the different toxins. To determine which pathway is utilized by PMT, we Toxins 2011, 3                       
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first sought whether PMT is internalized via the same pathway as Tfn, which traffics primarily through 
Arf6-positive early endosomes [33] and Rab5-associated recycling endosomes [44]. We examined the 
localization  of  a  GFP-tagged  N-terminal  fragment  (residues  1–568)  of  PMT  (PMTb-GFP),  which 
harbors the domains responsible for cellular binding and internalization [45]. We treated Swiss 3T3 
fibroblastic  cells  with  PMTb-GFP,  and  Tfn-TR  to  visualize  colocalization.  Both  PMTb-GFP  and  
Tfn-TR  were  distributed  in  vesicles  throughout  the  cytosol  (Figure  1A,B)  and  appeared  to  be 
colocalized within endosomes (Figure 1C). 
Figure 1. PMTb-GFP initially colocalizes with Tfn-Texas Red, but then diverges and is 
trafficked to endosomes through a PI3-kinase-independent process. Shown are confocal 
microscope  images  of  Swiss  3T3  cells  after  treatment  with  PMTb-GFP,  with  the 
endosomes marked by Transferrin-Texas Red (Tfn-TR). Cells were treated with 260 µg/mL 
PMTb-GFP and with 20 µg/mL Tfn-TR for 3.5 h to visualize the endosomes. Cells were 
visualized by confocal microscopy using a 40×  objective. (a) PMTb-GFP; (b) Tfn-TR;  
(c)  merged  image  of  (a)  and  (b);  (d)  corresponding  phase-contrast  image.  Inset: 
Enlargement of the indicated section of the image, showing co-localization of PMTb-GFP 
and Tfn-TR; (e) HEK 293-T cells were transiently transfected with dual SRE-luciferase 
reporter plasmids and pcDNA3-Gq as described in Methods. Seven h post-transfection 
cells were treated with LY294002 at the indicated concentrations and incubated for 15 min 
before treatment with 100 ng/mL PMT. After 15 h incubation, cells were harvested and 
assayed for SRE reporter gene activity, as described in Methods. SRE fold activation was 
determined by dividing SRE reporter gene activity in PMT-treated cells by SRE reporter 
gene  activity  in  untreated  control  cells.  Data  is  expressed  as  an  average  of  three 
experiments ±  S.D., with each experiment performed in triplicate, where ** p < 0.005;  
(f) HEK 293-T cell extracts treated with LY294002 at the indicated concentrations were 
subjected to western blot analysis to detect P-Akt and total Akt. 
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Figure  2.  PMTb-GFP  initially  colocalizes  with  CTxB-594,  but  then  diverges  and  is 
trafficked to and translocated from acidic endosomes. HEK 293-T cells were transiently 
transfected with dual SRE-luciferase reporter plasmids and pcDNA3-Gq as described in 
Methods. Seven h post-transfection cells were treated with (a) NH4Cl or (b) bafilomycin 
A1 (BAF) at the indicated concentrations for 15 min before treatment with 100 ng/mL 
rPMT. After 15  h incubation, cells  were harvested and assayed for SRE reporter gene 
activity, as described in the Methods. SRE fold activation was determined by dividing SRE 
reporter  gene  activity  in  PMT-treated  cells  by  SRE  reporter  gene  activity  in  untreated 
control  cells.  Data  is  expressed  as  an  average  of  three  experiments  ±   S.D.  with  each 
experiment performed in triplicate, where * p < 0.05, ** p < 0.005, and *** p < 0.000005. 
(c–j) Swiss 3T3 cells were co-treated with PMTb-GFP and CT subunit B Alexa Fluor
®-594 
conjugate  (CtxB-594)  for  3  h,  as  described  in  Methods,  without  (c–f)  or  with  (g–j) 
pretreatment  for  30  min  with  30  mM  NH4Cl.  Cells  were  visualized  by  confocal 
microscopy. Panels (c) and (g), PMTb-GFP. Panels (d) and (h), CtxB-594. Panels (e) and 
(i),  merged  images  of  green  and  red  channels.  Panels  (f)  and  (j),  corresponding  DIC 
images. Insets: Enlargement of the indicated section of the image, showing co-localization 
of PMTb-GFP and CtxB-594. 
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3.2.  PI3-Kinase-Mediated  Fusion  of  Arf6-Positive  and  EEA1/Rab5-Positive  Endosomes  Is  Not 
Necessary for PMT Intoxication 
It has been previously demonstrated that Arf6 is implicated in internalization of Tfn [33]. It is also 
known that Arf6-positive early endosomes can fuse with Rab5/EEA1-positive endosomes in a process 
that is dependent on PI 3-kinase [28] and that this process can be inhibited using LY294002, a specific 
and  reversible  inhibitor  of  PI  3-kinase  [46].  We  hypothesized  that  if  the  PMT-containing  early 
endosomes,  which  also  contain  Tfn,  fused  with  Rab5/EEA1-positive  endosomes,  then  this  fusion 
would be dependent on PI 3-kinase and therefore PMT trafficking could be prevented by treatment 
with LY294002. As shown in Figure 1E, pretreatment of HEK 293-T cells with LY294002 had no 
effect on rPMT-induced SRE-luciferase reporter activity at concentrations up to 75 µM and only a 
slight inhibitory effect at 100 µM; however, this concentration is twice that used to prevent the fusion 
of Arf6-positive and Rab5/EEA1-positive endosomes [28]. In control experiments, cell extracts were 
also blotted for phosphorylated Akt (P-Akt) and total Akt to demonstrate that LY294002 inhibited, as 
expected, phosphorylation and activation of Akt at concentrations of 10 µM or higher (Figure 1F). 
These results suggest that despite initial colocalization of PMTb with Tfn, a PI 3-kinase-mediated 
fusion event of Arf6-positive and Rab5/EEA1-positive endosomes is not necessary for PMT trafficking 
to a translocation-productive compartment. 
3.3. Intra-Endosomal Acidification Is a Crucial Step in PMT Intoxication 
Weak bases such as NH4Cl can be used to alkalinize endosomal pH [47]. Treating HEK-293T cells 
with 2 mM NH4Cl caused a dose-dependent decrease in PMT-induced SRE-luciferase reporter activity, 
with complete inhibition observed at concentrations above 5 mM (Figure 2A). Bafilomycin A1 (BAF), 
another specific inhibitor of endosomal acidification, slows the progression from early endosomes to 
late  endosomes  [27,48].  It  was  previously  demonstrated  that  BAF  inhibits  PMT-mediated 
phosphorylation of FAK in Swiss 3T3 cells [20]. Similarly, when HEK 293-T cells were treated with 
BAF 15 min prior to treatment with rPMT, there was a dose-dependent decrease in PMT-induced  
SRE-luciferase  reporter  activity  (Figure  2B).  Taken  together,  the  inhibition  of  PMT-induced  
SRE-luciferase reporter activity after treatment with BAF and NH4Cl demonstrates that acidification of 
the endosome is a crucial step in PMT intoxication of cells. 
3.4. Colocalization of PMTb with CT B Subunit 
In contrast to PMT, intra-endosomal acidification does not play a role in entry and translocation of 
CT [34,49], yet CT is present in Rab5-positive and Arf6-positive early endosomes and interacts with 
Arf6 during cellular intoxication [34,50]. A CT subunit B Alexa Fluor
®-594 conjugate (CtxB-594) was 
added  to  the  cells  concurrently  with  PMTb-GFP  and  the  distribution  patterns  were  observed  by 
confocal fluorescence microscopy after 3 h incubation in the absence or presence of 30mM NH4Cl 
(Figure 2C–J). In the absence of NH4Cl, PMTb-GFP showed a punctate localization that is spread 
throughout the cytosol and is colocalized with CTxB-594 (Figure 2C–F). In the presence of NH4Cl, the 
PMTb-GFP-containing endosomes localized to the periphery of the cell and did not colocalize with 
CTxB-594-containing  endosomes  (Figure  2G–J).  Moreover,  the  distribution  of  CtxB-594-positive Toxins 2011, 3                       
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endosomes was not affected by treatment with NH4Cl. These results demonstrate that in contrast to 
CtxB, a toxin where intra-endosomal acidification is not thought to be important for entry, blocking 
intra-endosomal  acidification  with  NH4Cl  drastically  affects  the  trafficking  and  localization  of  
PMTb-GFP. 
Figure 3. Arf6-dependent internalization and trafficking of PMT. HEK 293-T cells were 
transiently  transfected  with  dual  SRE-luciferase  reporter  plasmids,  pcDNA3-Gq,  and 
plasmids  containing  Arf6  or  Arf6  mutants,  as  described  in  Methods.  Seven  hours  
post-transfection cells were treated with 100 ng/mL PMT and incubated for 15 h before 
assaying for SRE reporter gene activity. SRE fold activation was determined by dividing 
SRE reporter gene activity in PMT treated cells by SRE reporter gene activity in untreated 
control cells. Fold activation was then normalized to empty vector control (pcDNA3). Data 
is expressed as an average of eight experiments ±  S.D., with each experiment performed in 
triplicate, where * p < 0.05 and ** p < 0.005. (b–i) Swiss 3T3 cells were co-treated with 
PMTb-GFP and cholera toxin subunit B Alexa Fluor
®-594 conjugate (CtxB-594) for 1 h 
(b–e) or 3 h (f–i). Cells were visualized by confocal microscopy. Panels (b) and (f), green 
channel  image  showing  PMTb-GFP.  Panels  (c)  and  (i),  red  channel  image  showing  
CtxB-594. Panels (d) and (h), merged images of green and red channels. Panels (e) and (i), 
corresponding  DIC  images.  Insets:  Enlargement  of  the  indicated  section  of  the  image, 
showing co-localization of PMTb-GFP and CtxB-594. 
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3.5. The Potential Role of Arf6 in Internalization and Trafficking of PMT 
Previous studies show that intra-endosomal acidification by the V-ATPase results in recruitment of 
the small GTPase Arf6 and its GDP/GTP exchange factor (GEF) ADP-ribosylation factor nucleotide 
site  opener  (ARNO)  to  the  endosomal  membrane  [22]  where  Arf6  binds  to  the  c-subunit  of  the  
V-ATPase while ARNO binds to the a2-isoform [23]. This pH-driven recruitment of ARNO has been 
shown to be important for both receptor-mediated endocytosis and for trafficking between early and 
late  endosomes.  Since  our  results  demonstrate  that  inhibitors  of  endosomal  acidification,  such  as  
NH4Cl  and  BAF,  inhibit  PMT-induced  SRE-luciferase  reporter  activity  (Figure  2)  and  that  PMT 
initially colocalizes with Tfn and CT in Arf6-positive vesicles, we hypothesized that the small GTPase 
Arf6 may play a role in internalization and trafficking of PMT. 
To investigate the role of Arf6 in PMT trafficking, we overexpressed wildtype and several mutants 
of Arf6 to observe their effects on rPMT induced SRE-luciferase reporter activity. Arf6 is a small 
GTPase that relies on hydrolysis of a bound GTP and subsequent release of GDP to function properly. 
Therefore, any Arf6 mutants that have defects in GTP hydrolysis and subsequent GDP release will 
have impaired activity. The Arf6 Q67L mutant is a constitutively active mutant, while the Arf6 T27N 
and  Arf6 T44N mutants are dominant-negative mutants. The Arf6 T157A mutant is constitutively 
cycling due to decreased binding of both GDP and GTP. 
Overexpression of wildtype Arf6 had no effect on PMT-induced SRE-luciferase reporter activity in 
HEK 293-T cells treated with rPMT (Figure 3A), in agreement with previous studies that showed 
overexpressing wildtype Arf6 does not perturb the function, localization or distribution of Arf6 [24]. 
On the other hand, overexpression of constitutively active Arf6 Q67L or dominant-negative Arf6 T44N 
reduced the activity by 50% and 30%, respectively. Overexpression of the Arf6 T157A constitutively 
cycling mutant also resulted in 50% inhibition. These data strongly suggest a regulatory role for Arf6 in 
the internalization of PMT, presumably by preventing PMT receptor-containing vesicles from cycling 
to the surface or by preventing formation of PMT-containing endosomes. There was no significant 
effect of overexpression of the dominant-negative Arf6 T27N mutant on rPMT induced SRE-luciferase 
reporter activity. However, this mutant is less stable than the Arf6 T44N mutant [51], so the observed 
lack of effect of Arf6 T27N could be a result of instability.  
Next we wanted to determine if the effects of overexpression of Arf6 mutants on rPMT activity 
were dependent on the trafficking activity of Arf6. It was previously demonstrated that mutating the 
glycine at position 2 of Arf6 to alanine results in a cytosolic, nonmyristolated Arf6 that does not 
associate with membranes and is unable to mediate endocytic trafficking [52]. We hypothesized that if 
a  mutant  Arf6  that  previously  demonstrated  inhibition  of  PMT-mediated  SRE-luciferase  reporter 
activity were mutated so that it could no longer associate with the membrane, then the ability of the 
mutant to decrease PMT intracellular activity would be abolished. To test this hypothesis, we chose the 
two mutants that showed the greatest inhibitory effect on PMT cellular activity, Arf6 Q67L and Arf6 
T157A, and made an additional mutation substituting alanine for glycine at position 2 in order to 
abolish  their  myristolation,  therefore  preventing  membrane  association.  Unlike  their  myristolated 
counterparts, the nonmyristolated Arf6 mutants, Arf6 G2A/Q67L and Arf6 G2A/T157A, did not block 
PMT-mediated SRE-luciferase reporter activity (Figure 3A). Taken together these results suggest that 
the inhibition of PMT-induced SRE-luciferase reporter activity observed with the Arf6 Q67L and the Toxins 2011, 3                       
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Arf6  T157A  mutants  is  a  direct  consequence  of  their  disruption  of  PMT  trafficking  through  
Arf6-containing vesicles inside the cell.  
To explore whether PMT may exploit a similar Arf6-dependent pathway for initial entry as CT [53], 
despite their differences in dependence on intra-endosomal acidification, we co-treated Swiss 3T3 cells 
with PMTb-GFP and CtxB-594 and observed the cellular distribution of both after 1 or 3 h by confocal 
fluorescence  microscopy  (Figure  3).  After  1  h,  PMTb-GFP  and  CtxB-594  were  both  observed  in 
punctate vesicles localized throughout the cell (Figure 3A,B, respectively) and were largely colocalized 
(Figure 3D). After 3 h, the PMTb-GFP was still located in punctate vesicles throughout the cell (Figure 
3F); however, co-treatment for 3 h resulted in divergence of PMTb-GFP from CtxB-594 (Figure 3H), 
with  an  accumulation  of  CtxB-594  to  the  perinuclear  region  (Figure  3G),  while  the  PMTb-GFP 
remained predominantly localized in punctate vesicles throughout the cell (Figure 3F). These results 
are consistent with previous research demonstrating that CtxB-594 is trafficked to the ER [39]. These 
data  suggest  that  while  PMTb-GFP  and  CTxB-594  may  initially  share  a  common  entry  pathway,  
CtxB-594 is then trafficked to the Golgi and subsequently to the ER, while PMT remains in endosomal 
compartments, which are subsequently subject to intra-endosomal acidification and rendered capable 
PMT translocation. 
3.6. PMT Trafficking Is Dependent on Actin Dynamics 
We next wanted to determine whether components of the cytoskeleton are important for PMT entry 
and  trafficking.  We  hypothesized  that  if  actin  dynamics  play  a  prominent  role  in  trafficking  and 
internalization of PMT, pre-treating cells with cytochalasin D, an inhibitor of actin polymerization, 
would  interfere  with  PMT  trafficking  pathways  thereby  inhibiting  rPMT-induced  SRE-luciferase 
reporter  activity.  To  determine  whether  actin  dynamics  play  a  significant  role  in  trafficking  and 
internalization of PMT, HEK 293-T cells were pre-treated with varying concentrations of cytochalasin 
D for 15 min before rPMT treatment. As shown in Figure 4A, cytochalasin D treatment caused a  
dose-dependent decrease in PMT-induced SRE-luciferase reporter activity, with complete inhibition at 
concentrations over 0.3 µM, pointing towards the importance of actin dynamics for internalization and 
trafficking of PMT. 
3.7. PMT Trafficking Is Dependent on Microtubule Dynamics 
Microtubules  are  required  for  trafficking  from  early  sorting  endosomes  to  late  acidic  
endosomes [27]. Consequently, we next investigated whether the PMT trafficking pathway is also 
dependent on microtubule dynamics. We hypothesized that if microtubule dynamics were important in 
the entry and trafficking of PMT, using an inhibitor of microtubule polymerization such as nocodazole 
would  inhibit  PMT-induced  SRE-luciferase  reporter  activity.  To  determine  if  disruption  of  the 
microtubule network also disrupts PMT trafficking, we pre-treated HEK 293-T cells with nocodazole, 
a microtubule inhibitor, for 15 min. As shown in Figure 4B, pre-treatment of HEK-293T cells with 
nocodazole caused a dose-dependent decrease in PMT-induced SRE-luciferase reporter activity, with 
complete  inhibition  observed  at  concentrations  of  1  µM  or  higher.  Taken  together  these  results 
demonstrate  that  both  actin  and  microtubule  dynamics  play  an  important  role  in  the  entry  and 
trafficking pathways of PMT. Toxins 2011, 3                       
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Figure  4.  Both  actin  and  microtubule  dynamics  are  important  for  PMT  trafficking  to 
translocation-productive  acidic  late  endosomes.  HEK  293-T  cells  were  transiently 
transfected with dual SRE-luciferase reporter plasmids and pcDNA3-Gq as described in 
Methods.  Seven  h  post-transfection  cells  were  treated  with  cytochalasin  D  (a)  or 
nocodazole (b) at the indicated concentrations for 15 min before treatment with 100 ng/mL 
PMT. After 15 h incubation, cells were assayed for SRE reporter gene activity, as described 
in Methods. SRE fold activation was determined by dividing SRE reporter gene activity in 
PMT-treated  cells  by  SRE  reporter  gene  activity  in  untreated  control  cells.  Data  is 
expressed as an average of three experiments ±  S.D., with each experiment performed in 
triplicate, where * p < 0.05 and ** p < 0.005. 
 
3.8. Treatment with Brefeldin A Causes an Increase in PMT Activity 
Brefeldin A (BFA) is a fungal metabolite that interrupts trafficking between the Golgi apparatus and 
the ER, leading to the accumulation of secretory proteins in the ER [40,54]. Treatment with BFA 
results in uncoating of the Golgi apparatus [55] and subsequent formation of tubulovesicular processes 
that redistribute the contents of the Golgi into the ER [56]. Although it was demonstrated that BFA 
treatment does not affect the distribution of Arf6 [24], BFA treatment does induce morphological 
changes in the distribution of early endosomes resulting in the formation of a tubular network similar 
to that seen during redistribution of the Golgi after treatment with BFA [57]. We next determined 
whether these morphological changes produced by BFA affected the entry and trafficking of PMT. 
Interestingly, pre-treatment of HEK-293T cells with BFA resulted in a dose-dependent increase in 
PMT-induced SRE-luciferase reporter activity (Figure 5A), with as much as a six-fold increase in PMT 
activity observed upon treatment with 1 µM BFA. These results suggest that the formation of a tubular 
endosomal system within the cell by BFA results in an increase in PMT activity. 
We  further  explored  this  phenomenon  by  determining  whether  translocation  of  PMT  from  the 
endosome was necessary for the observed BFA-mediated increase in PMT activity. We hypothesized 
that  if  translocation  from  the  endosome  were  necessary  for  the  BFA-mediated  increase  in  PMT 
activity, blocking translocation of PMT into the cytosol by treating with NH4Cl to prevent acidification 
of the endosome would effectively inhibit PMT activity. To test this possibility, HEK 293-T cells were 
pre-treated for 15 min with both 1 µM BFA and varying concentrations of NH4Cl up to 20 mM. As 
shown  in  Figure  5B,  treatment  of cells with  as  little as  2 mM  NH4Cl  significantly decreased the  
BFA-mediated increase in PMT activity, and indeed, at higher concentrations the inhibition by NH4Cl Toxins 2011, 3                       
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overrode  the  5-fold  activation  observed  in  the  absence  of  BFA.  These  data  suggest  that  the  
BFA-mediated increase in PMT activity is dependent on translocation of PMT to the cytosol from 
acidic endosomes. 
We then attempted to elucidate the mechanism of this BFA-mediated increase in PMT activity by 
determining  whether  this  effect  was  occurring  downstream  of  the  Arf6  involvement  in  PMT 
trafficking. We first overexpressed in HEK-293T cells the Arf6 mutants, Arf6 Q67L or Arf6 T157A, 
which we found to decrease PMT activity by preventing PMT entry and trafficking (Figure 3A). The 
cells were then treated with 1 µM BFA for 15 min, followed by PMT treatment as before. As shown in 
Figure 5C, there was no increase in PMT-induced SRE-luciferase reporter activity in cells expressing 
either Arf6 Q67L or Arf6 T157A, as compared to cells transfected with an empty vector. These data 
suggest that the entry and trafficking of PMT into the cell via an Arf6 pathway occurs upstream of the 
BFA-mediated increase in PMT activity. 
Next, we determined the localization of PMTb-GFP and CtxB-594 in cells pretreated with BFA. 
Swiss  3T3  cells  were  pretreated  with  1  µM  BFA  for  15  min  and  subsequently  co-treated  with  
PMTb-GFP and CtxB-594 for 3 h, after which the cellular distribution of the toxin proteins were 
visualized by confocal fluorescence microscopy (Figure 5D,E, respectively). After treatment for 3 h, 
the  PMTb-GFP  and  CtxB-594  appeared  colocalized  in  large  vesicles,  predominantly  near  the 
perinucleolar region (Figure 5F). These vesicles appeared to be larger than the PMTb-GFP containing 
vesicles observed in the absence of BFA treatment (compare with Figure 2C–E). 
4. Conclusions 
This study further defines the trafficking pathways PMT uses to gain access to its intracellular 
targets.  Previous  studies  showed  that  PMT  inserts  into  lipid  membranes  and  that  this  membrane 
insertion is pH-dependent [20] and occurs at a pH that causes PMT unfolding [21], suggesting that 
endosome acidification is important for the unfolding of PMT and its insertion into the membrane to 
form a translocation pore. In our experiments, we demonstrate that inhibiting endosomal acidification 
through the use of NH4Cl or BAF blocks PMT intracellular activity, as measured by PMT-mediated 
SRE-luciferase reporter activity. These results are in accordance with previous studies demonstrating 
that BAF inhibited PMT-mediated phosphorylation of FAK [20]. Interestingly, these earlier studies 
used BAF concentrations of 10–100 µM, a concentration range that is more than 1000-fold higher than 
the  concentration  used  in  the  current  study.  Taken  together  these  data  indicate  that  
intra-endosomal  acidification  is  an  essential  step  in  PMT  entry  and  translocation  to  the  cytosol. 
Preventing  intra-endosomal  acidification  blocks  this  translocation  step,  and  instead  PMT  remains 
trapped in the endosome with a concomitant block in downstream SRE-luciferase reporter activity. 
Blocking  intra-endosomal  acidification  also  affected  the  distribution  of  the  PMTb-GFP-containing 
vesicles  as  these vesicles were observed to accumulate near the membrane. In contrast,  CtxB-594 
trafficking was not affected as vesicles containing the CtxB-594 were distributed evenly throughout the 
cell. This would suggest that preventing intra-endosomal acidification not only blocks translocation 
and  traps  PMT  in  vesicles  that  remain  near  the  cell  membrane,  but  also  affects  trafficking  of  
PMTb-GFP-containing vesicles within the cell. Toxins 2011, 3                       
 
  
233 
Figure  5.  Treatment  with  brefeldin  A  enhances  PMT  activity.  HEK  293-T  cells  were 
transiently transfected with  dual SRE-luciferase reporter plasmids and pcDNA3-Gq as 
described in Methods. Seven h post-transfection cells were treated with brefeldin A (BFA) 
at the indicated concentrations (a) or with a combination of BFA (1 µM) and NH4Cl at the 
indicated concentrations (b) for 15 min before treatment with 100 ng/mL PMT. After 15 h 
incubation, the cells were assayed for SRE reporter gene activity as described in Methods. 
(c)  HEK  293-T  cells  were  transiently  transfected  with  dual  SRE-luciferase  reporter 
plasmids, pcDNA3-Gq, and plasmids containing Arf6 Q67L or Arf6 T157A, as described 
in Methods. Seven h post-transfection cells were treated with BFA (1 µM) for 15 min 
before treatment with 100 ng/mL PMT. After 15 h incubation, cells were assayed for SRE 
reporter gene activity as described in Methods. SRE fold activation was determined by 
dividing SRE reporter gene activity in PMT treated cells by SRE reporter gene activity in 
untreated control cells. Data is expressed as an average of two experiments ±  S.D., with 
each performed in triplicate, where * p < 0.005. (d–g) The effect of BFA (1 µM) on the 
localization of PMTb-GFP and CtxB-594 in Swiss 3T3 cells after 3 h incubation. Cells 
were visualized by confocal microscopy. Panel (d), green channel image showing PMTb-
GFP. Panel (e), red channel image showing CtxB-594. Panel (f), merged images of green 
and red channels. Panel (g), corresponding DIC image. Inset: Enlargement of the indicated 
section of the image, showing co-localization of PMTb-GFP (green) and CtxB-594 (red). 
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It has been demonstrated that intra-endosomal acidification recruits the small GTPase Arf6 to the 
endosomal membrane [22]. Overexpression of the constitutively active mutant of Arf6, Arf6 Q67L, 
results in a dramatic morphological change as many membrane invaginations labeled with Arf6 Q67L 
develop [24] and increases cell surface binding of transferrin (Tfn), while decreasing the rate of Tfn 
internalization [32,33]. This suggests that while the mutation results in increased binding of the ligand, 
the protein is unable to subsequently internalize it. It is thought that GTP hydrolysis is essential for 
Arf6 function and the GTPase-deficient Arf6 Q67L mutant results in a block in endocytosis through 
Arf6-mediated pathways [30,58]. Accordingly, our results showing that overexpression of Arf6 Q67L 
decreases PMT-mediated SRE-luciferase reporter activity supports the notion that the mutation blocks 
PMT endocytosis through Arf6-mediated pathways. 
Overexpression of the dominant-negative mutant of Arf6, Arf6 T27N, results in accumulation of the 
mutant Arf6 in tubulovesicle structures [24], suggesting that both GTP hydrolysis and release of GDP 
are necessary for Arf6 function. By disrupting the release of GDP, the dominant-negative mutant Arf6 
T44N, which is more stable than the T27N mutant, should also disrupt the Arf6 trafficking pathway. 
When  we  overexpressed  the  Arf6  T44N  mutant  we  observed  a  decrease  in  PMT-mediated  
SRE-luciferase reporter activity, further implicating the Arf6 pathway in the endocytic trafficking of 
PMT. The finding that the constitutively cycling mutant Arf6 T157A mutant, which binds, hydrolyzes 
and releases GTP faster than the wild-type Arf6 [59], also blocks PMT activity further supports these 
results. It has been suggested that Arf6 activation is responsible for returning recycling endosomes 
back to the plasma membrane [32]. Therefore it is possible that a quick cycling version of the mutant 
may  quickly  recycle  endosomes  back  to  the  membrane  thereby  preventing  acidification  of  the 
endosome.  If  the  PMT-containing  vesicles  were  recycled  to  the  surface  before  the  endosome  is 
acidified, then PMT would be unable to translocate to the cytosol and hence show decreased activity.  
Membrane localization of Arf6 is mediated through its N-terminal myristolation, and a mutation at 
the myristoylation site (Arf6 G2A) results in subsequent localization of Arf6 to the cytosol [24]. As our 
results show, abolishing this myristolation in the Arf6 Q67L or Arf6 T157A mutants prevents the 
decrease in PMT-mediated SRE-luciferase reporter activity brought about by overexpression of the 
mutants. This demonstrates that the decrease in PMT activity is dependent upon association of Arf6 
with the plasma membrane and upon Arf6-dependent trafficking functions, as cytosolic mutants of 
Arf6 showed no effect on PMT-induced SRE-luciferase reporter activity. 
As previously mentioned, Arf6 is not only an allosteric activator of CT [35,36], but also has been 
implicated  in  trafficking  of  CT.  Arf6  is  recruited  to  the  endosomal  membrane  in  CT-intoxicated  
cells  [34].  In  addition,  it  has  been  previously  demonstrated  that  Arf6  plays  a  role  in  uptake  of 
transferrin [33]. If PMT were to exploit the same initial trafficking pathway as CT and Tfn, then one 
would expect to see PMT colocalized in vesicles with CT and Tfn. Our results show that after 1 h of 
treatment PMTb-GFP does colocalize with CtxB-594 and Tfn-TR in punctate structures throughout the 
cell, suggesting that PMTb-GFP uptake occurs through Arf6-containing endosomes. However, after 
treatment for 3 h PMT trafficking diverges from that of CT and Tfn, as evidenced by the failure of  
PI3-kinase inhibitor LY294002, which blocks fusion with Rab5-positive recycling vesicles that are 
used by Tfn, to block PMT activity and by the buildup of CtxB-594 in the ER, while the PMTb-GFP 
remains localized in punctate vesicles throughout the cell. These results support a model, whereby Toxins 2011, 3                       
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PMT, Tfn, and CT may share an initial trafficking pathway in Arf6 positive vesicles, but then these 
pathways diverge as CT is trafficked to the Golgi-ER and Tfn to recycling endosomes, while PMT 
traffics to an acidified endosome from which it can translocate. 
Given the evidence that PMT, Tfn and CT diverge in their trafficking pathways, we wanted to 
further explore the trafficking pathways of PMT downstream of Arf6. Other toxins, such as DT, that 
exhibit  a  dependence  on  intra-endosomal  acidification  for  translocation  [60]  have  been  shown  to 
colocalize with Rab5 and early endosome markers such as EEA1 [61]. Studies have implicated the 
translocation  domain  of  DT  in  the  modulation  of  Rab5  activity  [62].  Vesicles  taken  up  by  
clathrin-independent endocytosis with Arf6 have been shown to recruit EEA1 to their surfaces before 
fusion  with  endosomes  from  other  pathways,  such  as  the  Rab5  Q79L  pathway.  However, 
overexpression  of  Arf6  Q67L  inhibits  recruitment  of  EEA1  and  subsequent  fusion  with  other 
endosomal pathways [28]. This fusion of Arf6 and Rab5-positive vesicles was mediated by the activity 
of  PI-3  kinase,  as  specific  inhibitors  of  PI-3  kinase  such  as  LY294002  prevent  this  fusion  from 
occurring [28]. If PMT were acting in a manner similar to DT by exploiting Rab5 pathways for entry 
into the cell, it is conceivable that PMT/Arf6-positive vesicles would fuse with Rab5-positive vesicles 
in a PI-3 kinase dependent manner. However, the specific PI-3 kinase LY294002 had no effect on PMT 
SRE-luciferase  reporter  activity,  despite  decreasing  phosphorylation  of  Akt,  suggesting  that  the  
Arf6-Rab5  PI-3  kinase-mediated  fusion  of  vesicles  is  not  important  for  PMT  trafficking  
and translocation.  
Not only have we shown that PMT is trafficked through a compartment with Arf6, we have also 
demonstrated the importance of the cytoskeleton in these trafficking pathways. Our results indicate that 
PMT trafficking is dependent upon both actin and microtubule dynamics, implicating both actin and 
microtubules in the trafficking pathways that PMT uses to enter the cell. To further investigate where 
the PMT and CT trafficking pathways diverge, we investigated the effects of brefeldin A (BFA) on 
PMT-mediated SRE-luciferase activity. BFA is a fungal metabolite that interrupts trafficking between 
the Golgi apparatus and the ER and causes accumulation of secretory proteins in the ER [40,54], 
uncoating of the Golgi apparatus  [55], and subsequent formation of tubulovesicular processes that 
redistribute the contents of the Golgi into the ER [56]. Furthermore, trafficking through the Golgi 
cisternae is interrupted. It has been previously demonstrated that CT has a KDEL signal sequence [39] 
and that the toxin is trafficked in a retrograde manner from the Golgi to the ER, where it escapes to the 
cytoplasm to affect its intracellular target Gs. Interrupting this retrograde trafficking pathway from the 
Golgi to the ER with addition of BFA blocks CT-mediated cAMP accumulation [41].  
Our colocalization experiments demonstrated that, unlike CTxB-TR, PMTb-GFP was not trafficked 
to the ER. If PMTb-GFP were not trafficked to the ER, then BFA treatment would not be expected to 
affect PMT-mediated SRE-luciferase activity. However, we saw an increase in SRE-luciferase activity 
when cells were treated with BFA. Interestingly, VacA from Helicobacter pylori has also been shown 
to exhibit increased activity upon treatment with BFA [63]. There are several potential explanations for 
this increase. In addition to its effects on the Golgi apparatus, BFA induces similar effects on the 
endosomal system and causes the tubulation of both the endosomal system, as well as lysosomes. 
Although this mixed system is able to cycle between endosomes and the plasma membrane in a normal 
fashion, cycling between endosomes and lysosomes is impaired [57]. By impairing the pathway from Toxins 2011, 3                       
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the early endosome to the lysosome, PMT that may have otherwise been routed to a lysosome instead 
accumulates  in  the  acidified  endosome  and  translocates  to  the  cytosol,  resulting  in  the  observed 
increased activity. Similarly, perhaps during the course of PMT trafficking, a fraction of the PMT is 
shuttled  through  the  Golgi  to  the  ER,  where  it  is  unable  to  escape  to  the  cytosol.  Blocking  this  
non-productive  trafficking  through  the  use  of  BFA  results  in  more  PMT  trapped  in  the  acidic 
endosomes and thus available for translocation.  
However, other data suggests that while the morphology of the endosomal system is changed by 
BFA,  cycling  between  the  early  endosome  and  the  lysosome  is  not  impaired  [64].  If  a  block  in 
trafficking  to  the  lysosome  is  not  responsible  for  the  increase  in  PMT-mediated  SRE–luciferase 
reporter activity brought about by BFA treatment, perhaps the morphological changes induced by BFA 
to form tubular endosomes results in the observed increase in PMT activity. It is possible that more 
PMT  is  able  to  translocate  from  the  tubular  endosomes,  thereby  resulting  in  an  increase  in  PMT 
activity.  Furthermore,  studies  have  demonstrated  that  this  BFA-induced  tubulovesicle  network 
associates with microtubules [65]. The association with microtubules is especially noteworthy as the 
decrease  in  PMT  activity  seen  with  nocodazole  implicates  microtubules  as  part  of  the  trafficking 
pathway of PMT. 
Alternatively, perhaps BFA treatment is responsible for increasing the number of PMT cell surface 
receptors. It has been shown that treatment with BFA increases the amount of cell-surface associated 
mannose-6-phosphate  receptor  (M6PR)  [65].  Although  a  protein  receptor  for  PMT  is  as  of  yet 
unidentified, it is possible that BFA induces an increase in the amount of a putative plasma membrane 
associated receptor, thereby allowing more PMT to bind to the cell surface and enter  the cell via  
Arf6-mediated  endocytosis.  Further  studies  are  needed  to  elucidate  the  mechanism  of  this  
BFA-mediated increase in PMT activity. 
By overexpressing the Arf6 Q67L mutant that inhibited endocytosis, we were able to block the 
effects of BFA. This would suggest that the BFA mediated increase in PMT activity depends on PMT 
initially entering the cell. In addition, we showed that treating the cells with NH4Cl blocks the BFA 
mediated increase in PMT activity, indicating that translocation is necessary for this BFA-mediated 
increase  in  PMT  activity.  These  results  support  the  assertion  that  the  increase  in  SRE-luciferase 
reporter activity after treatment with BFA is dependent on the ability of PMT to enter the cell via 
endocytosis and to translocate from the endosome.  
In summary, we have implicated the Arf6 trafficking route as a potential mode of entry for PMT. A 
model of PMT entry and trafficking that incorporates our findings as well as previous findings is 
shown  in  Figure  6.  We  have  demonstrated  dependence  on  intra-endosomal  acidification  for 
translocation and trafficking of PMT. These data suggest that PMT may share an initial entry pathway 
with Tfn and CT, but these pathways later diverge as Tfn is trafficked to Rab5-positive recycling 
endosomes  and  CT  is  trafficked  in  a  retrograde  fashion  from  the  Golgi  to  the  ER,  while  PMT 
translocates  from  an  acidified  late  endosome.  In  addition,  we  have  shown  the  importance  of 
cytoskeletal dynamics of both actin and microtubules in PMT trafficking pathways. Finally, we have 
shown that BFA increases PMT activity, through an as-yet ill-defined mechanism that leads to more 
productive trafficking of the toxin to an acidic compartment for translocation. 
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Figure  6.  A  model  of  PMT  entry  and  trafficking.  PMT  enters  the  cell  through  an  
Arf6-dependent endocytic pathway that involves both actin and microtubule dynamics as 
evidenced by inhibition of PMT-mediated SRE activation upon expression of Arf6 mutants 
(Arf6-CA or Arf6-DN) or treatment with the inhibitors cytochalasinD (CcD) or nocodazole 
(Noc), respectively. PMT shares a similar route of endocytosis as  transferrin (Tfn) and 
cholera toxin (CT); however, these pathways subsequently diverge. Tfn-bound receptors 
are trafficked to a Rab5-containing endosome in a PI 3-kinase-dependent vesicle fusion 
process,  which  is  inhibited  by  LY294002.  CT  is  trafficked  retrograde  through  the  
trans-Golgi  network  (TGN)  to  the  Golgi-ER.  PMT  is  further  trafficked  through  an 
endocytic  vesicle  that  becomes  acidified  prior  to  translocation  of  PMT  to  the  cytosol. 
Inhibitors of endosomal acidification, such as NH4Cl and bafilomycin A1 (BafA1), block 
the translocation of PMT, while brefeldin A (BFA) enhances this process by diverting any 
trafficking of PMT to the TGN instead to the acidified endocytic vesicles. 
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